Clinical Trials Arena is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Obizur Antihemophilic Factor (recombinant) for the Treatment of Acquired Haemophilia A

Drug Name (Brand / Generic)

Obizur (anti-haemophilic factor (recombinant))

Developed by

Baxter International

Therapy class

Recombinant DNA derived anti-haemophilic factor

Current Indication

Acquired Haemophilia A

Market Sector

Genetics

Development Status

Approved in the US
Expand
Close
Close
Close

Go Top